Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

SVB Leerink Maintains Outperform on Regeneron Pharmaceuticals, Raises Price Target to $850

SVB Leerink analyst Geoffrey Porges maintains Regeneron Pharmaceuticals (NASDAQ:REGN) with a Outperform and raises the price target from $798 to $850.
byBenzinga Newsdesk
November 5, 2021
1 minute read
Total
0
Shares
0
0
0
0
0
0

SVB Leerink analyst Geoffrey Porges maintains Regeneron Pharmaceuticals (NASDAQ:REGN) with a Outperform and raises the price target from $798 to $850.

 
Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Share 0